Advertisement

Recruitment and Retention

  • Stephen P. Glasser

Abstract

Nothing is more important to a clinical research study than recruiting and then retaining subjects in a study. In addition, losses to follow-up and destroy a study. This chapter will address such issues as to why people participate in clinical research, what strategies can be employed to recruit and then retain subjects in a study, issues involved with minority recruitment, and HIPAA; and, will include some real examples chosen to highlight the retention of potential drop-outs.

Keywords

Protect Health Information Clinical Research Study Covered Entity Tuskegee Syphilis Study Minority Recruitment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Charlson ME, Horwitz RI. Applying results of randomised trials to clinical practice: impact of losses before randomisation. Br Med J (Clin Res Ed). Nov 10, 1984; 289(6454):1281–1284.CrossRefGoogle Scholar
  2. 2.
    Easterbrook PJ, Matthews DR. Fate of research studies. J R Soc Med. Feb 1992; 85(2):71–76.PubMedGoogle Scholar
  3. 3.
    A case study in how not to conduct a clinical trial. USA Today, 2000.Google Scholar
  4. 4.
    Wright JR, Bouma S, Dayes I, et al. The importance of reporting patient recruitment details in phase III trials. J Clin Oncol. Feb 20, 2006; 24(6):843–845.PubMedCrossRefGoogle Scholar
  5. 5.
    Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med. July 2, 2002; 137(1):10–16.PubMedGoogle Scholar
  6. 6.
    Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol. Feb 1, 2006; 163(3):197–203.PubMedCrossRefGoogle Scholar
  7. 7.
    Halpern SD. Reporting enrollment in clinical trials. Ann Intern Med. Dec 17, 2002; 137(12):1007–1008; author reply 1007–1008.PubMedGoogle Scholar
  8. 8.
    Hewison J, Haines A. Overcoming barriers to recruitment in health research. BMJ. Aug 5, 2006; 333(7562):300–302.CrossRefGoogle Scholar
  9. 9.
    Getz K. Industry trials poised to win back academia after parting ways in the late 90s. Appl Clin Trials. Apr 1, 2007; 2007.Google Scholar
  10. 10.
    Giuffrida A, Torgerson DJ. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ. Sept 20, 1997; 315(7110):703–707.PubMedGoogle Scholar
  11. 11.
    Dunn LB, Gordon NE. Improving informed consent and enhancing recruitment for research by understanding economic behavior. JAMA. Feb 2, 2005; 293(5):609–612.PubMedCrossRefGoogle Scholar
  12. 12.
    Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. June 2000; 82(11):1783–1788.PubMedCrossRefGoogle Scholar
  13. 13.
    Hawkins C, West T, Ferzola N, Preismeyer C, Arnett D, Glasser S. Why do patients participate in clinical research? Associates of Clinical Pharmacology 1993 Annual Meeting; 1993.Google Scholar
  14. 14.
    Mapstone J, Elbourne DR, Roberts I. Strategies to improve recruitment in research studies; 2002.Google Scholar
  15. 15.
    Gilliss C, Lee K, Gutierrez Y, et al. Recruitment and Retention of Healthy Minority Women into Community-Based Longitudinal Research. J Womens Health Gender-Based Med. 2001; 10:77–85.CrossRefGoogle Scholar
  16. 16.
    Yancy AK, Ortega AN, Kumanyika SK. Effective recruitment and retention of minority research participants. Annu Rev Public Health. 2006; 27:1–28.CrossRefGoogle Scholar
  17. 17.

Copyright information

© Springer Science + Business Media B.V 2008

Authors and Affiliations

  • Stephen P. Glasser
    • 1
  1. 1.Univesity of Alabama at Birmingham, Birmingham, AlabamaBirmingham

Personalised recommendations